Outcomes and cost‐effectiveness comparisons of progestin‐primed ovarian stimulation, GnRH antagonist protocol, and luteal phase stimulation for fertility preservation
International Journal of Gynecology & Obstetrics · 2023-11 · 163 (2) · 645-650
DOI: 10.1002/ijgo.14903 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 02.06.2023. Verfasst von Weie Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medicine Research Center, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Progestins, Fertility Preservation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
To compare the clinical outcomes and cost‐effectiveness of progestin‐primed ovarian stimulation (PPOS) and the gonadotropin‐releasing hormone‐antagonist (GnRH‐A) protocol in fertility preservation (FP) in cancer patients. The stimulation option when patients were in the luteal phase was also explored.
Methods
This retrospective study analyzed clinical data from 163 patients who underwent FP. The number of retrieved oocytes and vitrified oocytes/embryos, total dose of gonadotropin, duration of stimulation, number of injections, and cost were compared among the PPOS, GnRH‐A, and luteal phase stimulation (LPS) groups.
Results
No significant differences were noted in the numbers of retrieved oocytes and vitrified oocytes/embryos among the three groups. In the multiple regression model, age ( P = 0.02) and antral follicle count (AFC) ( P < 0.001), but not the controlled ovarian stimulation (COS) protocols ( P = 0.586), were associated with the number of retrieved oocytes. The number of injections and the cost were all significantly lower in the PPOS and LPS groups than in the GnRH‐A group( P < 0.001).
Conclusion
PPOS had similar clinical results but was superior medically and economically to GnRH‐A. For patients in the luteal phase, LPS was an optional protocol with similar outcomes and costs to PPOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reproductive Medicine Research Center, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Förderung
- the National Key Research and Development Program of China
Zitieren
APA
Zhao, W., Sun, P., Li, T., Li, Y., Liang, X., & Li, J. (2023). Outcomes and cost‐effectiveness comparisons of progestin‐primed ovarian stimulation, GnRH antagonist protocol, and luteal phase stimulation for fertility preservation. International Journal of Gynecology & Obstetrics, 163(2), 645-650. https://doi.org/10.1002/ijgo.14903
Vancouver
Zhao W, Sun P, Li T, Li Y, Liang X, Li J. Outcomes and cost‐effectiveness comparisons of progestin‐primed ovarian stimulation, GnRH antagonist protocol, and luteal phase stimulation for fertility preservation. International Journal of Gynecology & Obstetrics. 2023;163(2):645-650. doi:10.1002/ijgo.14903
BibTeX
@article{Zhao2023,
author = {Zhao, Weie and Sun, Peng and Li, Tingting and Li, Yongfang and Liang, Xiaoyan and Li, Jingjie},
title = {Outcomes and cost‐effectiveness comparisons of progestin‐primed ovarian stimulation, GnRH antagonist protocol, and luteal phase stimulation for fertility preservation},
journal = {International Journal of Gynecology & Obstetrics},
year = {2023},
volume = {163},
number = {2},
pages = {645--650},
doi = {10.1002/ijgo.14903}
}
EUVIMED